Adherence to hypertension and dyslipidemia treatment and its implication on control of cardiovascular disease in Vietnam: A semi-systematic review.

BACKGROUND: To understand the prevalent issues and challenges in the provision of care for dyslipidemia and hypertension in Vietnamese adults, quantification of patient journey stages (awareness, screening, diagnosis, treatment, adherence, and control) was performed in this semi-systematic review. METHODS: The EMBASE and MEDLINE databases were searched for English articles published between 2010 and 2019. Thesis abstracts, letters to the editor, editorials, case studies, and studies on patient subgroups or nationally unrepresentative studies, were excluded. Articles from Google, the Incidence and Prevalence Database, the World Health Organization, Vietnam's Ministry of Health, and those suggested by the authors were also included. The last search was run on December 10, 2019 for dyslipidemia and hypertension. RESULTS: A reviewer independently screened 586 retrievals for dyslipidemia and 177 retrievals for hypertension, and extracted data from 2 articles on dyslipidemia and 6 articles on hypertension that were included in the final synthesis. CONCLUSION: The data generated in this review will help overcome these issues and barriers to patient care in populations with these 2 conditions.

Pulmonary mucoepidermoid lung carcinoma in pediatric confused with asthma.

Pulmonary mucoepidermoid carcinoma (PMEC) is an extremely rare tumor of the respiratory system. The clinical presentation of PMEC is variable and nonspecific, including cough, hemoptysis, and wheezing, and may mimic other symptoms of pneumonia or asthma. Here, we present a case of PMEC in a 12-year-old male who was diagnosed with and treated for asthma for 2 years. The patient presented with symptoms of respiratory failure that did not respond to steroids or bronchodilator medications. Chest computed tomography (CT) scans revealed an endotracheal tumor. The patient underwent complete tumor resection, with no signs of recurrence 6 months after treatment.